Clinical Trial Search

Primary: Adverse Events (AEs) Affecting Ocular Function That Differ Clinically From Those Expected in the Normal Course of Progression of XLRS — 3; 3; 12; 6 events

Primary: Safety and Tolerability of AGI-134 Injected Intra-tumourally (IT) — 0; 0; 0; 0 Participants

Primary: Change in Gene Expression Typically Associated With Atopic Dermatitis in Lesional Skin Biopsies From Baseline to Week 4 — 0.212; 0.043; 0.155; 0.048 fold change

Primary: Objective Response Rate (ORR) — 7.7 percentage of participants

Primary: Assessment of the Pharmacodynamic Effect of CIVI 007 — -4.54; -71.38; -76.01; -82.27 percentage change from baseline — p=<0.0001

Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Adverse Events of Special Interest (TEAESIs) and Treatment-emergent Serious…

Primary: Overall Response — 3; 3; 3; 2 Participants

Primary: Mean and Standard Deviation (SD) of the AGS Scale at 52 Weeks — 5.9 score on a scale — p=<0.0005

Primary: 18F-FES Uptake in DCIS — 1.43 SUV

Primary: Objective Response Rate — 0 Participants

Primary: Maximum Tolerated Dose (MTD) (Part 1 Only) — 400 milligrams (mg) once per day

Primary: Percentage of Safety Events (Part 1, Japan Only) — 5; 0 Participants

Primary: Pharmacokinetics (PK) in Adults - Systemic Clearance (CL) — 6.14 liters/hour

Primary: Objective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator — 66.7; 50.0 Percentage of Participants